RxDoctor Payments Data

Michael Kam, MD

Gastroenterology · Rochester Hills, MINPI 1316040504

Payments from drug & device makers

$14,309in general payments, 2019–2025

Across 688 payments — averaging $20.80 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$4K
  • Takeda Pharmaceuticals U.S.A., Inc.$2K
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$1K
  • Johnson & Johnson$1K
  • Regeneron Healthcare Solutions, Inc.$527
  • Ironwood Pharmaceuticals, Inc$513
  • plus $5K from 32 others

What the payments were for

  • Food & beverage$14,309100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$14,309 in reported general payments places this provider in the 80th percentile of 497 gastroenterology providers in Michigan.

See all gastroenterology providers in Michigan

Medicare billing

Part B allowed, 2024
$275,396
Medicare patients
706
Services billed
2,432

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
CreonLipase/Protease/Amylase22$87,614
LinzessLinaclotide60$64,797
XifaxanRifaximin14$42,012
Mesalamine18$24,038
Dexlansoprazole DrDexlansoprazole12$4,209
Omeprazole188$3,256
ClenpiqSod Picosulf/Mag Ox/Citric Ac18$3,055
Famotidine165$2,641
CholestyramineCholestyramine (With Sugar)25$2,270
Sucralfate54$1,785
Budesonide EcBudesonide14$1,632
Ursodiol11$1,628
Gavilyte-GPeg3350/Sod Sulf,bicarb,cl/Kcl66$1,297
Budesonide DrBudesonide12$1,129
Pantoprazole Sodium55$859

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieCreon, Linzess$3,594$152,41082 claims
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan$1,338$42,01214 claims
Ferring Pharmaceuticals Inc.Clenpiq$49$3,05518 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 497 gastroenterology providers in Michigan.

Other gastroenterology in Rochester Hills

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →